BCM
MRNS

BluePath Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

BluePath Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,730
Closed -$38.1K – 337
2023
Q3 		$38.1K Buy
+4,730
New +$39.3K 0.04% 209

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

BluePath Capital Management's MRNS Position: Q4 2023 in Review

BluePath Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2023, closing a stake of 4,730 shares — an estimated $38.1K sold.

BluePath Capital Management first reported a position in MRNS in Q3 2023 and held it in 1 quarter. The position peaked at $38.1K in Q3 2023. 105 funds tracked by Wall St. Rank hold MRNS as of Q4 2023.

  • BluePath Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
  • BluePath Capital Management sold 4,730 Marinus Pharmaceuticals, Inc shares in Q4 2023, an estimated $38.1K.
  • BluePath Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2023 and held it in 1 quarter.
  • BluePath Capital Management's Marinus Pharmaceuticals, Inc position peaked at $38.1K in Q3 2023.
  • 105 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2023.

Based on BluePath Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.